Association Between Neopterin Levels and Outcome in 30 Day HIV/AIDS Naive Patients

Lydia Juanita, Usman Hadi, Vitanata Arfijanto

Abstract views = 297 times | downloads = 242 times


Introduction: HIV/AIDS is still a major problem throughout the world even in Indonesia. Some markers can provide information regarding the description of immune activity in HIV/AIDS. Neopterin produced by macrophages as a catabolic result of Guanosine Triphosphate (GTP) is one of them. Neopterin has been widely studied as a prognostic indicator of the course in HIV/AIDS. Until now there have been no studies examine the association between neopterin levels and outcomes in 30 days of HIV/AIDS patients.

Methods: A prospective longitudinal analytic study involved 56 samples of HIV/AIDS naive patients from January to April 2019. Serum neopterin levels were measured by the Enzyme Linked Immunosorbent Assay (ELISA) method. Outcome is a living condition or death within the first 30 days of the patient being treated. Discriminant function analysis was used to determine the association between variable and controlling confounding factors using the "R" program. Outputs of p value was significant if <0.05.

Results: The average age of the study subjects was 39.7 ± 11 years old with predominantly male gender (71.4%). The median serum neopterin level of the study subjects was 168.13 nmol/L with the lowest levels of 11.78 nmol/L and the highest level of 196.95 nmol/L. Outcomes were grouped live and died, each group at 50%. There was a significant positive association between serum neopterin levels and outcomes in 30 days (p=0.02)

Conclusion: Role of neopterin levels still need to be proven as a prognostic factor by evaluating other factors that influence the outcome of HIV/AIDS patients.


HIV/AIDS; serum neopterin levels; outcome 30 days

Full Text:



Mildvan D, Spritzler J, Grossberg S, Fahey JL, Johnston, Schock B, Kagan J. Serum Neopterin, an Immune Activation Marker, Independently Predicts Disease Progression in Advanced HIV-1 Infection. Clinical Infectious Diseases. 2005; 40:853-858.

Bipath P, Viljoen M, Levay PF. Levels of Procalcitonin, C-reactive protein and Neopterin in patients with advanced HIV-1 infection. South African Journal Medicine. 2012; 13(2): 78-82

Data and Information Center. The Situation of HIV/AIDS in Indonesia. Data and Information Center of Ministry of Health Republic of Indonesia. 2017. [Online] Available from: [Accessed on Juli, 29 2018].

Ministry of Health Republic of Indonesia. HIV-AIDS problem situation, reports on the progress of HIV-AIDS. Directorate General of Disease Prevention and Control. 2017. [Online] Available from: [Accessed on Juli, 29 2018].

Nasronudin. HIV & AIDS. HIV eradication and antiretroviral therapy strategies. Clinis and social molecular biology approaches, 2nd Edn. Airlangga University Press, Surabaya. 2014; pp.583 – 600.

Bipath P, Levay P, Olorunju S, Viljoen M. A non-spesific of disease activity in HIV/AIDS patients from resource-limited environments. South African Journal Medicine. 2015; 15(2): 334-343.

Geng EH, Odeny TA, Lyamuya RE, Nakiwogga-Muwanga A, Diero L, Bwana M, Muyindike W, Braitstein P, Somi GR, Kambugu A, Bukusi EA, Wenger M, Wools-Kaloustian K, Glidden DV, Yiannoutsos CT, Martin J. Estimation of Mortality Among HIV infected people on antiretroviral therapy treatment in east Africa: a sampling based approach in an observasional, multisite, cohort study. Lancet HIV. 2015; 2(3):e107-e116.

Lartey M, Asante A, Essel A, Kenu E, Ganu V, Neequaye A. Causes of Death in Hospitalized HIV Patients in the Early Anti-Retroviral Therapy Era. Ghana Medical Journal. 2015; 49(1):7-11.

Saavedra A, Campinha N, Hajjar M, Kenu E, Syeda F, Obo-Akwa A, Lartey M, Kwara A. Causes of death and factors associated with early mortality of HIV-infected adults admitted to Korle-Bu Teaching Hospital. The Pan African Medical Journal. 2017; 1-7.

Low M, Geffen N. When to start antiretroviral treatment? A history and anlysis of a scientific controversy. Southern African Journal of HIV Medicine. 2017; 18(1).

Wachter H, Fuchs D, Hausen A, Huber C, Knosp O, Reibnegger G, Spira T. Elevated urinary Neopterin levels in patientswith the acquired immunodeficiency syndrome (AIDS). Hoppe Seyler’s Physiology Chemical. 1983; 364:1345-1346.

Fuchs D, Hausen A, Reibnegger G, Reissgl H, Spira T, Wachter H. Urinary Neopterin in the diagnosis of acquired immune deficiency syndrome. European Journal of Clinical Microbiology. 1984; 3:70-71.

Wirleitner B, Schroecksnadel K, Winkler C, Fuchs D. Neopterin in HIV-1 infection. Molecular Immunology. 2004; 42:183-194.

Centers for Medicare & Medicaid Services (CMS). CMS 30-Day Hospital Mortality Measures. 2007 [Online] Available from [Accessed on Juli,15 2018].

Nazar KP, Jankowska A. Clinical Usefulness of Determining the Concentration of Neopterin. Pteridines. 2011; 22(3)77-89

Neopterin. 2018 [Online] Available from: [Accessed on Juli, 15 2018].

Larrosa PF, Croci DO, Riva DO, Bibini M, Luzzi R, Saracco M, Mersich SE. Apoptosis Resistance in HIV-1 Persistently-infected cells is Independent of Active Viral Replication and Involves Modulation of the Apoptotic Mitochondrial Pathway. Retrovirology. 2008; 5(19): 1-12.

Larsen M, Bayard C, Bittan J, Appay V, Boddaert J, Sauce D. Elevated Neopterin Levels Predict Early Death in Older Hip-Fracture Patients. Ebiomedicine. 2017; 26: 157-164.

Sacktor N, Liu X, Popescu M, Marder K, Stern Y, Mayeux R. Serum Neopterin Level Predict HIV-Related Mortality but Not Progression to AIDS or Development of Neurological Disease in Gay Men and Parenteral Drug Users. Archives of Neurology. 1995; 52: 676-679.

Hosp M, Quigley M, Mwinga AM, Godfrey FP, Porter JDH, McAdam KPWJ, Fuchs D. 2000. Neopterin and Other Indicators of HIV Progression in Zambian Adults. Pteridines. 2000; 11(2): 37-42.


  • There are currently no refbacks.

Copyright (c) 2019 Lydia Juanita, Usman Hadi, Vitanata Arfijanto

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.



Creative Commons License

This Journal (E-ISSN:2620-8636) is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

View BHSJ Stats